Abstracts tagged "longitudinal studies"

Abstract Number: 1008 • 2013 ACR/ARHP Annual Meeting
Longitudinal Analysis Of Direct Medical Costs For Systemic Sclerosis Patients: A Population-Based Study
Natalie McCormick¹, Carlo A. Marra², Eric C. Sayre³ and J. Antonio Avina-Zubieta⁴, ¹Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada
Background/Purpose: Patients with systemic sclerosis (SSc) have considerable morbidity which may be associated with high health resource utilization. Studies on health use and costs are…
Abstract Number: 901 • 2013 ACR/ARHP Annual Meeting
Smokers and Overweight Persons Are At Increased Risk Of New Onset Of Severe Foot Pain and Persistent Severe Foot Pain In a Population Study
Alyssa B. Dufour¹, Hylton B. Menz², Arunima Awale³, Thomas J. Hagedorn³, Virginia A. Casey³, Patricia P. Katz⁴ and Marian T. Hannan⁵, ¹Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School & Beth Israel Deaconess Medical Center, Boston, MA, ²Lower Extremity and Gait Studies Program, La Trobe University, Bundoora, Victoria 3086, Australia, ³Institute for Aging Research, Hebrew SeniorLife, Boston, MA, ⁴Medicine, University of California, San Francisco, San Francisco, CA, ⁵Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Few studies have evaluated risk factors for patterns of foot pain in the general population, let alone over time. An understanding of the possible…
Abstract Number: 882 • 2013 ACR/ARHP Annual Meeting
Association Of a Neutrophil Gene Signature Comprised Of Low Density Granulocyte (LDG)-Enriched Genes With Both Future Systemic Lupus Erythematosus Disease Activity and Poor Longterm Outcomes
Michelle Petri¹, Laurence S. Magder², Hong Fang¹, Jadwiga Bienkowska³, Andrea Dearth⁴, Norm Allaire⁵ and Ann Ranger⁴, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Biogen Idec Inc, Cambridge, MA, ⁵Biogen Idec Inc., Cambridge, MA
Background/Purpose: Neutrophils and neutrophil death (NETosis) have a role in the pathogenesis of SLE. A neutrophil gene signature (NGS) exists in SLE, although its association…
Abstract Number: 739 • 2013 ACR/ARHP Annual Meeting
Cardiac Involvement In Granulomatosis With Polyangiitis
Lucy McGeoch¹, Simon Carette², David Cuthberston³, Gary S. Hoffman⁴, Nader A. Khalidi⁵, Curry L Koening⁶, Carol A. Langford⁷, Paul A. Monach⁸, Larry W. Moreland⁹, Philip Seo¹⁰, Ulrich Specks¹¹, Steven R. Ytterberg¹², Carol McAlear¹³, Peter A Merkel¹⁴, Christian Pagnoux² and The Vcrc¹⁵, ¹Vasculitis clinic, Division of rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ³Biostatistics, University of South Florida, Tampa, FL, ⁴Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁵Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ⁷Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology, Boston University, Boston, MA, ⁹Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁰Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹¹Mayo Clinic, Rochester, MN, ¹²Rheumatology Division, Mayo Clinic, Rochester, MN, ¹³University of Pennsylvania, Philadelphia, PA, ¹⁴Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ¹⁵University of Pennsylvania and VA Medical Center, Philadelphia, PA
Background/Purpose: Prior cohort studies in Europe have found cardiac involvement to be rare in granulomatosis with polyangiitis (GPA) but associated with significant increases in mortality…
Abstract Number: 392 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Cardiovascular Risk Factors and Cardiovascular Disease In Rheumatoid Arthritis Patients Across International Regions: A Comparison Of The Corrona International and Corrona United States Registries
Dimitrios A. Pappas¹, Kathy Lampl², Joel M. Kremer³, Sebastião C. Radominski⁴, Janos Gal⁵, Fredrik Nyberg⁶, Anand N. Malaviya⁷, Aimée Whitworth⁸, Oscar Luis Rillo⁹, Allan Gibofsky¹⁰, Tatiana Popkova¹¹, Meilien Ho¹², Ieda Laurindo¹³, George W. Reed⁸, Eduardo Mario Kerzberg¹⁴, Laura Horne¹⁵, Roman Záhora¹⁶, Katherine C. Saunders¹⁷, Bernado Pons-Estel¹⁸, Alina U. Onofrei¹⁹ and Jeffrey D. Greenberg²⁰, ¹Columbia University, New York, NY, ²AstraZeneca R&D Wilmington, Wilmington, DE, ³Center for Rheumatology, Albany Medical College, Albany, NY, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵Rheumatology, County Hospital, Kecskemet, Hungary, ⁶AstraZeneca R&D, Mölndal, Sweden, ⁷Rheumatology, Consultant Rheumatologist, ISIC Superspeciality Hospital, New Delhi-11007-, India, ⁸CORRONA, Inc., Southborough, MA, ⁹Hospital Tornú, Capital Federal, Argentina, ¹⁰Medicine and Public Health, Hospital for Special Surgery, New York, NY, ¹¹Research Institute of Rheumatology -Russian Academy of Medical Science, Moscow, Russia, ¹²AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ¹³Rheumatology, Universidade de São Paulo, São Paulo, Brazil, ¹⁴Rheumatology, J. M. Ramos Mejía Hospital, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina, ¹⁵AstraZeneca, Wilmington, DE, ¹⁶Revmatologická ambulance, Terezin, Czech Republic, ¹⁷Corrona, LLC., Southborough, MA, ¹⁸Hospital Provincial de Rosario, Rosario, Argentina, ¹⁹University of Massachusetts Medical School, Worcester, MA, ²⁰Rheumatology, NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Cardiovascular disease (CVD) is a major comorbidity in patients (pts) with rheumatoid arthritis (RA). We explored variations in the prevalence of cardiovascular (CV) risk…
Abstract Number: 290 • 2013 ACR/ARHP Annual Meeting
Children With JIA Show Distinct Patterns Of Improvement In Their Health-Related Quality Of Life During The First Year On Treatment: Growth Mixture Modeling Of a Prospective Cohort Of Newly Diagnosed Patients
Bin Huang¹, Chen Chen², Stacey Niehaus³, Hermine Brunner⁴, Rina Mina⁵ and Michael Seid⁶, ¹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH, ²Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH, ⁵Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pulmonary, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH
Background/Purpose: Health-related quality of life (HRQOL) is a key outcome in clinical care and research for children with JIA. Despite excellent clinical control and the…
Abstract Number: 251 • 2013 ACR/ARHP Annual Meeting
Physical Activity Is Associated With Reduced Incident Disability: Evidence From The Osteoarthritis Initiative
Dorothy D. Dunlop¹, Jing Song¹, Pamela A. Semanik², Leena Sharma², Joan M. Bathon³, Charles Eaton⁴, Marc C. Hochberg⁵, Rebecca D. Jackson⁶, C. Kent Kwoh⁷, W, Jerry Mysiw⁶, Michael C. Nevitt⁸ and Rowland W. Chang¹, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Chicago, IL, ³Columbia University, New York, NY, ⁴Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Providence, RI, ⁵Medicine, University of Maryland School of Medicine, Baltimore, MD, ⁶Ohio State University, Columbus, OH, ⁷School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA
Background/Purpose: Over 56 million people in the U.S. are classified as disabled. Physical activity is a low cost, broadly applicable approach to improve cardiovascular fitness,…
Abstract Number: 2161 • 2012 ACR/ARHP Annual Meeting
Methotrexate Polyglutamate Concentrations in Erythrocytes Are a Potential Tool for Therapeutic Drug Monitoring of Methotrexate Response in Rheumatoid Arthritis
Maurits C.F.J. De Rotte¹, Ethan den Boer², Maja Bulatovic³, Saskia M.F. Pluijm⁴, Johanna M.W. Hazes⁵ and Robert De Jonge¹, ¹Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, ²Clinical Chemistry, Erasmus University Hospital, Rotterdam, Netherlands, ³Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, ⁴Public Health, Erasmus Medical center, Rotterdam, Netherlands, ⁵Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…
Abstract Number: 2134 • 2012 ACR/ARHP Annual Meeting
The Changed Prognosis of Patients with Early Rheumatoid Arthritis
Karin Britsemmer¹ and Dirkjan van Schaardenburg², ¹Rheumatology, Jan van Breemen Research Institute / Reade, Amsterdam, Netherlands, ²Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
The Changed Prognosis of Patients with Early Rheumatoid Arthritis Background/Purpose: The treatment of rheumatoid arthritis (RA) has changed greatly during the past fifteen to twenty…
Abstract Number: 2068 • 2012 ACR/ARHP Annual Meeting
Is There a Difference in Rheumatology Patient Reported Outcomes When Measured At Home Versus the Clinic Setting?
C.J. Inman¹, Frederick Wolfe² and Kaleb Michaud³, ¹Pediatric Administration, University of Utah, Salt Lake City, UT, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Registries have become a common tool for collecting patient-centered outcome measures. Clinical effectiveness research may be improved if data from multiple registries could be…
Abstract Number: 1587 • 2012 ACR/ARHP Annual Meeting
Despite Low Disease Activity Patients with Poly- and Dermatomyositis Perceive Activity Limitation, Reduced Grip Force and Quality of Life Longitudinally
Malin Regardt¹, Marie-Louise Schult², Ingrid E. Lundberg³ and Elisabet MB Welin Henriksson⁴, ¹Department of Occupational Therapy, Department of Neurobiology, Care Sciences and Society, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet., Stockholm, Sweden, ³Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Medicine, Karolinska Institutet Rheum, Stockholm, Sweden
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are characterized by proximal muscle weakness. A recent study has shown that patients with PM and DM have reduced…
Abstract Number: 1278 • 2012 ACR/ARHP Annual Meeting
Tuberculosis and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
Kevin L. Winthrop¹, S.-H. Park², A. Gul³, M. Cardiel⁴, JJ Gomez-Reino⁵, D. Ponce de Leon⁶, R. Riese⁷, R. Chew⁷, T. Kawabata⁷, E. Mortensen⁶ and H. Valdez⁸, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²The Catholic University of Korea, Seoul, South Korea, ³Istanbul University, Istanbul, Turkey, ⁴Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, ⁵Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁶Pfizer Inc., Collegeville, PA, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc., New York, NY
Background/Purpose: Biologic therapies that block tumor necrosis factor-alpha (TNF) increase the risk of tuberculosis (TB), and screening for latent tuberculosis infection (LTBI) before their initiation…
Abstract Number: 1282 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months
Jurgen Wollenhaupt¹, Joel C. Silverfield², Eun Bong Lee³, Susan P. Wood⁴, Koshika Soma⁵, Lisy Wang⁴, Hiroyuki Nakamura⁶, Yoshihiro Komuro⁶, Chudi I. Nduaka⁴, David Gruben⁴, Birgitta Benda⁷, Samuel H. Zwillich⁵, Richard Riese⁴ and John D. Bradley⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Japan Inc., Tokyo, Japan, ⁷Pfizer Inc., Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy in RA. Here we report the safety…
Abstract Number: 1125 • 2012 ACR/ARHP Annual Meeting
Three Trajectories of Activity Limitations in Early Symptomatic Knee Osteoarthritis: A 5-Year Follow-up Study
Jasmijn F. M. Holla¹, Marike van der Leeden¹, Leo D. Roorda², Martijn W. Heymans³, Sita M.A. Bierma-Zeinstra⁴, Maarten Boers⁵, Willem F. Lems⁶, Martijn P.M. Steultjens⁷ and Joost Dekker⁸, ¹Amsterdam Rehabilitation Research Center, Reade, Amsterdam, Netherlands, ²Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ³Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ⁴Orthopaedics and General Practice, Erasmus MC - University Medical Center, Rotterdam, Netherlands, ⁵Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ⁶Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁷Institute for Applied Health Research and School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, Scotland, ⁸Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Knee osteoarthritis (OA) is one of the leading causes of activity limitations among older adults. The course of activity limitations is highly variable; some…
Abstract Number: 1126 • 2012 ACR/ARHP Annual Meeting
Comparison between Osteoartritis Initiative and CHECK study (Cohort Hip & Cohort Knee); Development of pain and function during 4 years follow-up
Janet Wesseling¹, Sita M.A. Bierma-Zeinstra², Margreet Kloppenburg³, Johannes WJ Bijlsma⁴ and CHECK steering group⁵, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Orthopaedics and General Practice, Erasmus MC - University Medical Center, Rotterdam, Netherlands, ³Department Rheumatology and Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands, Leiden, Netherlands, ⁴Dept of Rheumatology & Immun, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Dept of Rheumatology & Immun, University Medical Center Utrecht, Utrecht
Background/Purpose: Pain and disability related to osteoarthritis (OA) may generally be considered to be chronic, but it is known that its course can be very…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].